Funding From Alzheimer’s Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials SEATTLE, April 13, 2017 (GLOBE NEWSWIRE) -- As the first investor in M3 Biotechnology, the Alzheimer’s Drug Discovery Foundation (ADDF) helped validate the therapeutic potential of M3’s drug...